The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1666
December 26, 2022
View Complete Issue         Table of Contents 2019 
Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation
December 26, 2022 (Issue: 1666)
The FDA has approved a sublingual film formulation of the alpha-2 adrenergic receptor agonist dexmedetomidine (Igalmi — BioXcel Therapeutics) for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation
Article code: 1666b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.